CERE News and Press, Ceres Inc. From 12/06/23

2023-12-06 16:06:57 ET More on Cerevel Therapeutics Cerevel Stock Soars Ahead Of Parkinson's Drug Update - I'm On Sidelines Cerevel Therapeutics: High Standards And Development Burden Poses Reflexivity Risks Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2023 Earnings...

2023-12-06 14:05:40 ET Summary Cerevel Therapeutics Holdings, a neuroscience company, has seen its stock rise over 250% since its listing on the Nasdaq via a SPAC merger. The company recently conducted a $450 million at-the-market fundraising and its stock has risen over 45% this ...

Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Na...

2023-11-28 12:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...

2023-11-02 10:48:54 ET Summary Cerevel Therapeutics is a pre-revenue company focused on developing therapies for several neurological diseases. The company's main products in development include Emraclidine for schizophrenia and psychosis in Alzheimer's disease, Darigabat for epil...

2023-11-01 16:57:11 ET Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2023 Earnings Call Transcript November 01, 2023, 08:00 AM ET Company Participants Matt Calistri - Vice President of Investor Relations Ron Renaud - President and Chief Executive Officer Ray Sanc...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

2023-11-01 06:31:38 ET More on Cerevel Therapeutics Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity Cerevel Therapeutics prices $450M stock Cerevel downgraded at Bank of America on delayed readouts Seeking Alpha’s Quant Rating ...

Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference ...